AGPS and juvenile idiopathic arthritis: It is clinically important to take into consideration the fact that not alldetectable neutralising ADAs had impact on clinical outcomes (e.g. tocilizumab ADAslowered treatment response in children with JIA but less in adults with RA).Neutralising ADAs were more commonly found in patients treated with mAbs comparedwith fusion proteins; however, not all ADAs against mAbs had neutralising propertiesor impact on clinical efficacy (e.g. ADAs against ixekizumab were predominantlynon-neutralising and did not influence clinical response).